{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:29:34Z","timestamp":1784089774610,"version":"3.55.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,4,21]],"date-time":"2016-04-21T00:00:00Z","timestamp":1461196800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1038\/nrclinonc.2016.59","type":"journal-article","created":{"date-parts":[[2016,4,21]],"date-time":"2016-04-21T07:55:54Z","timestamp":1461225354000},"page":"270-272","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Generic imatinib \u2014 impact on frontline and salvage therapy for CML"],"prefix":"10.1038","volume":"13","author":[{"given":"Larry","family":"Gorkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,21]]},"reference":[{"key":"BFnrclinonc201659_CR1","unstructured":"NOVARTIS. Novartis Q4 and FY 2015 condensed financial report. [online] , (2016)."},{"key":"BFnrclinonc201659_CR2","unstructured":"REUTERS. Sun hopes cut-price generic Gleevec will win third of U.S. market. [online] , (2016)."},{"key":"BFnrclinonc201659_CR3","doi-asserted-by":"publisher","first-page":"djw003","DOI":"10.1093\/jnci\/djw003","volume":"108","author":"WV Padula","year":"2016","unstructured":"Padula, W. V. et al. Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States. J. Natl Cancer Inst. 108, djw003 (2016).","journal-title":"J. Natl Cancer Inst."},{"key":"BFnrclinonc201659_CR4","doi-asserted-by":"publisher","first-page":"3372","DOI":"10.1002\/cncr.29512","volume":"121","author":"J Chhatwal","year":"2015","unstructured":"Chhatwal, J., Mathisen, M. & Kantarjian, H. Are high drug prices for hematologic malignancies justified? A critical analysis. Cancer 121, 3372\u20133379 (2015).","journal-title":"Cancer"},{"key":"BFnrclinonc201659_CR5","unstructured":"Institute for Clinical and Economic Review. Evaluating the value of new drugs. [online] , (2015)."},{"key":"BFnrclinonc201659_CR6","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1182\/blood.V124.21.738.738","volume":"124","author":"RA Larson","year":"2014","unstructured":"Larson, R. A. et al. What is the most cost-effective strategy for treating newly diagnosed chronic phase chronic myeloid leukemia (CML) after Imatinib loses patent exclusivity? Blood 124, 738 (2014).","journal-title":"Blood"},{"key":"BFnrclinonc201659_CR7","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1182\/blood-2015-11-680058","volume":"127","author":"GH Jones","year":"2016","unstructured":"Jones, G. H., Carrier, M. A., Silver, R. T. & Kantarjian, H. Strategies that delay or prevent the timely availability of affordable generic drugs in the United States. Blood 127, 1398\u20131402 (2016).","journal-title":"Blood"},{"key":"BFnrclinonc201659_CR8","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1001\/jamaoncol.2015.1024","volume":"6","author":"H Kantarjian","year":"2015","unstructured":"Kantarjian, H., Mathisen, M. S. & Lipton, J. H. Having 'skin in the game' and allowing cross-border importation of drugs to lower high prices of cancer drugs. JAMA Oncol. 6, 729\u2013730 (2015).","journal-title":"JAMA Oncol."},{"key":"BFnrclinonc201659_CR9","unstructured":"Knox, R. Cancer drug mark-ups: year of Gleevec costs $159 to make but sells for $106K. CommonHealth [online] , (2015)."},{"key":"BFnrclinonc201659_CR10","unstructured":"Beasley, D. Pfizer hikes U.S. prices for over 100 drugs on January 1. REUTERS [online] , (2016)."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2016.59.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2016.59","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrclinonc.2016.59.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T03:31:08Z","timestamp":1684467068000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrclinonc.2016.59"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,21]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["BFnrclinonc201659"],"URL":"https:\/\/doi.org\/10.1038\/nrclinonc.2016.59","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,21]]},"assertion":[{"value":"21 April 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}